Zonisamide

Last updated
Zonisamide
Zonisamide structure.svg
Zonisamide molecule ball.png
Clinical data
Trade names Zonegran, Zonisade
AHFS/Drugs.com Monograph
MedlinePlus a603008
License data
Pregnancy
category
  • AU:D
Routes of
administration 		By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability ~100% [4]
Protein binding 40% [4]
Metabolism Liver through CYP3A4 [4]
Elimination half-life 63 hours in plasma [4]
Excretion Kidney (62%); Faeces (3%) [4]
Identifiers
  • benzo[d]isoxazol-3-ylmethanesulfonamide
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
PDB ligand
CompTox Dashboard (EPA)
ECHA InfoCard 100.118.526 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C8H8N2O3S
Molar mass 212.22 g·mol−1
3D model (JSmol)
Melting point 162 °C (324 °F)
  • O=S(=O)(N)Cc2noc1ccccc12
  • InChI=1S/C8H8N2O3S/c9-14(11,12)5-7-6-3-1-2-4-8(6)13-10-7/h1-4H,5H2,(H2,9,11,12) Yes check.svgY
  • Key:UBQNRHZMVUUOMG-UHFFFAOYSA-N Yes check.svgY
   (verify)

Zonisamide, sold under the brand name Zonegran among others, is a medication used to treat the symptoms of epilepsy and Parkinson's disease. [5] [6] Chemically it is a sulfonamide. It serves as an anticonvulsant used primarily as an adjunctive therapy in adults with Parkinson's disease, partial-onset seizures; infantile spasm, mixed seizure types of Lennox–Gastaut syndrome, myoclonic and generalized tonic clonic seizure. [7] Despite this it is also sometimes used as a monotherapy for partial-onset seizures. [6] [8]

Contents

In 2020, it was the 276th most commonly prescribed medication in the United States, with more than 1 million prescriptions. [9] [10]

Medical uses

Epilepsy

Zonisamide is approved in the United States, [2] [11] and United Kingdom [12] for adjunctive treatment of partial seizures in adults and Japan for both adjunctive and monotherapy for partial seizures (simple, complex, secondarily generalized), generalized (tonic, tonic-clonic (grand mal), and atypical absence) and combined seizures. [13] In Australia it is marketed as both an adjunctive therapy and monotherapy for partial seizures only. [8]

Parkinson's disease

It has been approved for the treatment of the motor symptoms of Parkinson's disease (PD), as an adjunct to levodopa, in a few countries such as Japan. [5] [6] In Japan, zonisamide has been used as an adjunct to levodopa treatment since 2009. [14] In addition, there is clinical evidence that zonisamide in combination with levodopa control of motor symptoms of PD but evidence for the treatment of the non motor symptoms of PD lacking. [15] [16]

Adverse effects

Adverse effects by incidence: [4] [17] [18]

Very common (>10% incidence) adverse effects include:

Common (1–10% incidence) adverse effects include:

Incidence unknown

Interactions

Zonisamide and other carbonic anhydrase inhibitors such as topiramate, furosemide, and hydrochlorothiazide have been known to interfere with amobarbital, which has led to inadequate anesthetization during the Wada test. [20] Zonisamide may also interact with other carbonic anhydrase inhibitors to increase the potential for metabolic acidosis. [4]

Additionally, the metabolism of zonisamide is inhibited by ketoconazole, ciclosporin, miconazole, fluconazole and carbamazepine (in descending order of inhibition) due to their effects on the CYP3A4 enzyme. [21]

Zonisamide is not known to inhibit cytochrome P450 enzymes when present at therapeutic concentrations. [22]

Mechanism of action

Zonisamide is an antiseizure drug chemically classified as a sulfonamide and unrelated to other antiseizure agents. The precise mechanism by which zonisamide exerts its antiseizure effect is unknown, although it is believed that the drug blocks sodium and T-type calcium channels, which leads to the suppression of neuronal hypersynchronization (that is, seizure-form activity). [8] It is also known to be a weak carbonic anhydrase inhibitor (similarly to the anticonvulsant topiramate). It is also known to modulate GABAergic and glutamatergic neurotransmission. [8] [23] [24] [25] [26]

Pharmacokinetics

Absorption

Variable, yet relatively rapid rate of absorption with a time to peak concentration of 2.8–3.9 hours. Bioavailability is close to 100% and food has no effect on the bioavailability of zonisamide but may affect the rate of absorption. [27] [22]

Metabolism

Zonisamide is metabolized mostly by the CYP3A4 isoenzyme, but also CYP3A7 and CYP3A5, [28] to 2-(sulphamoylacetyl)-phenol via reductive cleavage of the 1,2-benzisoxazole ring. [29]

History

Zonisamide was discovered by Uno and colleagues in 1972 [30] and launched by Dainippon Sumitomo Pharma (formerly Dainippon Pharmaceutical) in 1989 as Excegran in Japan. [31] It was marketed by Élan in the United States starting in 2000 as Zonegran, before Élan transferred their interests in zonisamide to Eisai Co., Ltd. in 2004. [32] Eisai also markets Zonegran in Asia (China, Taiwan, and fourteen others) [33] and Europe (starting in Germany and the United Kingdom). [34]

Research

Tardive dyskinesia

In an open-label trial zonisamide attenuated the symptoms of tardive dyskinesia. [35]

Obesity

It has also been studied for obesity [36] with significant positive effects on body weight loss and there are three ongoing clinical trials for this indication. [37] [38] [39] It was to be sold, when combined with bupropion, under the brand name Empatic, until its development was discontinued. [40]

Migraine

Zonisamide has been studied for and used as a migraine preventative medication, when topiramate is either ineffective or cannot be continued due to side effects. [6]

Bipolar depression

It has also been used off-label by psychiatrists as a mood stabilizer to treat bipolar depression. [41] [42]

Related Research Articles

<span class="mw-page-title-main">Valproate</span> Medication used for epilepsy, bipolar disorder and migraine

Valproate are medications primarily used to treat epilepsy and bipolar disorder and prevent migraine headaches. They are useful for the prevention of seizures in those with absence seizures, partial seizures, and generalized seizures. They can be given intravenously or by mouth, and the tablet forms exist in both long- and short-acting formulations.

Anticonvulsants are a diverse group of pharmacological agents used in the treatment of epileptic seizures. Anticonvulsants are also increasingly being used in the treatment of bipolar disorder and borderline personality disorder, since many seem to act as mood stabilizers, and for the treatment of neuropathic pain. Anticonvulsants suppress the excessive rapid firing of neurons during seizures. Anticonvulsants also prevent the spread of the seizure within the brain.

<span class="mw-page-title-main">Topiramate</span> Medication used to treat epilepsy and migraine

Topiramate, sold under the brand name Topamax among others, is a medication used to treat epilepsy and prevent migraines. It has also been used in alcohol dependence and essential tremor. For epilepsy this includes treatment for generalized or focal seizures. It is taken orally.

<span class="mw-page-title-main">Levetiracetam</span> Medication

Levetiracetam, sold under the brand name Keppra among others, is a medication used to treat epilepsy. It is used for partial-onset, myoclonic, or tonic–clonic seizures and is taken either by mouth as an immediate or extended release formulation or by injection into a vein.

<span class="mw-page-title-main">Donepezil</span> Medication used for dementia

Donepezil, sold under the brand name Aricept among others, is a medication used to treat dementia of the Alzheimer's type. It appears to result in a small benefit in mental function and ability to function. Use, however, has not been shown to change the progression of the disease. Treatment should be stopped if no benefit is seen. It is taken by mouth or via a transdermal patch.

<span class="mw-page-title-main">Eisai (company)</span> Japanese pharmaceutical company

Eisai Co., Ltd. is a Japanese pharmaceutical company headquartered in Tokyo, Japan. It has some 10,000 employees, among them about 1,500 in research. Eisai is listed on the Tokyo Stock Exchange and is a member of the Topix 100 and Nikkei 225 stock indices.

<span class="mw-page-title-main">4-Aminopyridine</span> Chemical compound

4-Aminopyridine (4-AP, fampridine, dalfampridine) is an organic compound with the chemical formula C5H4N–NH2. The molecule is one of the three isomeric amines of pyridine. It is used as a research tool in characterizing subtypes of the potassium channel. It has also been used as a drug, to manage some of the symptoms of multiple sclerosis, and is indicated for symptomatic improvement of walking in adults with several variations of the disease. It was undergoing Phase III clinical trials as of 2008, and the U.S. Food and Drug Administration (FDA) approved the compound on January 22, 2010. Fampridine is also marketed as Ampyra (pronounced "am-PEER-ah," according to the maker's website) in the United States by Acorda Therapeutics and as Fampyra in the European Union, Canada, and Australia. In Canada, the medication has been approved for use by Health Canada since February 10, 2012.

Bial is a pharmaceutical company headquartered in São Mamede do Coronado, in Trofa, Porto district, Portugal. It was founded in 1924, being among the largest companies of its kind in Portugal. Its products are sold in pharmacies in more than 58 countries in 4 continents: Europe, America, Africa and Asia.

<span class="mw-page-title-main">Rasagiline</span> Chemical compound

Rasagiline is an irreversible inhibitor of monoamine oxidase-B used as a monotherapy to treat symptoms in early Parkinson's disease or as an adjunct therapy in more advanced cases.

<span class="mw-page-title-main">Carbonic anhydrase inhibitor</span> Class of pharmaceuticals

Carbonic anhydrase inhibitors are a class of pharmaceuticals that suppress the activity of carbonic anhydrase. Their clinical use has been established as anti-glaucoma agents, diuretics, antiepileptics, in the management of mountain sickness, gastric and duodenal ulcers, idiopathic intracranial hypertension, neurological disorders, or osteoporosis.

<span class="mw-page-title-main">Rufinamide</span> Chemical compound

Rufinamide is an anticonvulsant medication. It is used in combination with other medication and therapy to treat Lennox–Gastaut syndrome and various other seizure disorders. Rufinamide, a triazole derivative, was developed in 2004 by Novartis Pharma, AG, and is manufactured by Eisai.

<span class="mw-page-title-main">Droxidopa</span> Synthetic amino acid/norepinephrine prodrug

Droxidopa is a synthetic amino acid precursor which acts as a prodrug to the neurotransmitter norepinephrine (noradrenaline). Unlike norepinephrine, droxidopa is capable of crossing the protective blood–brain barrier (BBB).

Arotinolol is a medication in the class of mixed alpha/beta blockers. It also acts as a β3 receptor agonist. A 1979 publication suggests arotinolol as having first been described in the scientific literature by Sumitomo Chemical as "β-adrenergic blocking, antiarrhythmic compound S-596".

<span class="mw-page-title-main">Perospirone</span> Atypical antipsychotic medication

Perospirone (Lullan) is an atypical antipsychotic of the azapirone family. It was introduced in Japan by Dainippon Sumitomo Pharma in 2001 for the treatment of schizophrenia and acute cases of bipolar mania.

<span class="mw-page-title-main">Pimavanserin</span> Atypical antipsychotic medication

Pimavanserin, sold under the brand name Nuplazid, is an atypical antipsychotic which is approved for the treatment of Parkinson's disease psychosis and is also being studied for the treatment of Alzheimer's disease psychosis, schizophrenia, agitation, and major depressive disorder. Unlike other antipsychotics, pimavanserin is not a dopamine receptor antagonist.

<span class="mw-page-title-main">Perampanel</span> Anti-epileptic medication

Perampanel, sold under the brand name Fycompa, is an anti-epileptic medication developed by Eisai Co. that is used in addition to other drugs to treat partial seizures and generalized tonic-clonic seizures for people older than twelve years. It was first approved in 2012, and as of 2016, its optimal role in the treatment of epilepsy relative to other drugs was not clear. It was the first antiepileptic drug in the class of selective non-competitive antagonist of AMPA receptors.

<span class="mw-page-title-main">Dasotraline</span> Chemical compound

Dasotraline is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) that was under development by Sunovion for the treatment of attention-deficit hyperactivity disorder (ADHD) and binge eating disorder (BED). Structurally, dasotraline is a stereoisomer of desmethylsertraline (DMS), which is an active metabolite of the marketed selective serotonin reuptake inhibitor (SSRI) antidepressant sertraline (Zoloft).

<span class="mw-page-title-main">Sumitomo Pharma</span> Pharmaceutical company based in Japan

Sumitomo Pharma Co., Ltd. is a pharmaceutical company based in Japan. Its headquarters are in Chuo-ku, Osaka.

<span class="mw-page-title-main">Lemborexant</span> Chemical compound

Lemborexant, sold under the brand name Dayvigo, is an orexin antagonist medication which is used in the treatment of insomnia. It is indicated specifically for the treatment of insomnia characterized by difficulties with sleep onset and/or maintenance in adults. The medication is taken by mouth.

<span class="mw-page-title-main">Ulotaront</span> Investigational antipsychotic drug

Ulotaront is an investigational antipsychotic that is undergoing clinical trials for the treatment of schizophrenia and Parkinson's disease psychosis. The medication was discovered in collaboration between PsychoGenics Inc. and Sunovion Pharmaceuticals using PsychoGenics' behavior and AI-based phenotypic drug discovery platform, SmartCube. Ulotaront is in Phase III of clinical development.

References

  1. ↑ "Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 30 March 2024.
  2. 1 2 "Zonegran- zonisamide capsule". DailyMed. 20 August 2021. Archived from the original on 27 January 2021. Retrieved 19 July 2022.
  3. ↑ "Zonisade- zonisamide suspension". DailyMed. 15 July 2022. Retrieved 21 January 2023.
  4. 1 2 3 4 5 6 7 "Zonegran Product Information" (PDF). TGA eBusiness Services. SciGen (Australia) Pty Ltd. 4 April 2013. Archived from the original on 15 October 2018. Retrieved 18 November 2013.
  5. 1 2 Grover ND, Limaye RP, Gokhale DV, Patil TR (November–December 2013). "Zonisamide: a review of the clinical and experimental evidence for its use in Parkinson's disease". Indian Journal of Pharmacology. 45 (6): 547–55. doi: 10.4103/0253-7613.121266 . PMC   3847242 . PMID   24347760.
  6. 1 2 3 4 Brayfield A, ed. (8 March 2016). "Zonisamide: Martindale: The Complete Drug Reference". MedicinesComplete. London, UK: Pharmaceutical Press. Archived from the original on 27 August 2021. Retrieved 19 August 2017.
  7. ↑ Souney P, Mutnick A, Shargel L (2007). Comprehensive Pharmacy Review (6th ed.). Williams & Wilkins. p. 988. ISBN   9780781765619. OCLC   869677890.
  8. 1 2 3 4 Rossi S, ed. (2013). Australian Medicines Handbook (2013 ed.). Adelaide: The Australian Medicines Handbook Unit Trust. ISBN   978-0-9805790-9-3.
  9. ↑ "The Top 300 of 2020". ClinCalc. Retrieved 7 October 2022.
  10. ↑ "Zonisamide - Drug Usage Statistics". ClinCalc. Retrieved 7 October 2022.
  11. ↑ "Drug Approval Package: Zonegran (Zonisomide) NDA #20-789". U.S. Food and Drug Administration (FDA). 24 December 1999. Archived from the original on 29 March 2021. Retrieved 20 July 2022.
  12. ↑ Eisai Ltd. (2005). "Zonegran Summary of Product Characteristics". electronic Medicines Compendium. Medicines.org.uk. Archived from the original on 8 November 2005. Retrieved 13 November 2005.
  13. ↑ Dainippon Pharmaceutical Co., Ltd. (2004). "EXCEGRAN Tablets 100 mg & EXCEGRAN Powder 20%" (PDF). Archived from the original (PDF) on 2007-09-28. Retrieved 13 March 2006.
  14. ↑ Murata M, Hasegawa K, Kanazawa I (January 2007). "Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study". Neurology. 68 (1): 45–50. doi:10.1212/01.wnl.0000250236.75053.16. PMID   17200492. S2CID   894677.
  15. ↑ Grover ND, Limaye RP, Gokhale DV, Patil TR (2013). "Zonisamide: a review of the clinical and experimental evidence for its use in Parkinson's disease". Indian Journal of Pharmacology. 45 (6): 547–55. doi: 10.4103/0253-7613.121266 . PMC   3847242 . PMID   24347760.
  16. ↑ Matsunaga S, Kishi T, Iwata N (2017). "Combination Therapy with Zonisamide and Antiparkinson Drugs for Parkinson's Disease: A Meta-Analysis". Journal of Alzheimer's Disease. 56 (4): 1229–1239. doi:10.3233/JAD-161068. PMID   28157097.
  17. ↑ "Zonegran 25, 50, 100 mg Hard Capsules". electronic Medicines Compendium. Eisai Ltd. 8 October 2013. Archived from the original on 12 January 2015. Retrieved 18 November 2013.
  18. ↑ "zonisamide (Rx) - Zonegran". Medscape Reference. WebMD. Archived from the original on 4 December 2013. Retrieved 18 November 2013.
  19. ↑ Karaduman AB, Kilic V, Atli-Eklioglu O, Baysal M, Aydogan-Kılıc G, Ucarcan S, et al. (December 2019). "Reproductive toxic effects and possible mechanisms of zonisamide in male rats". Human & Experimental Toxicology. 38 (12): 1384–1396. Bibcode:2019HETox..38.1384K. doi:10.1177/0960327119871094. PMID   31476894. S2CID   201804214.
  20. ↑ Bookheimer S, Schrader LM, Rausch R, Sankar R, Engel J (February 2005). "Reduced anesthetization during the intracarotid amobarbital (Wada) test in patients taking carbonic anhydrase-inhibiting medications". Epilepsia. 46 (2): 236–43. doi: 10.1111/j.0013-9580.2005.23904.x . PMID   15679504. S2CID   20730895.
  21. ↑ Nakasa H, Nakamura H, Ono S, Tsutsui M, Kiuchi M, Ohmori S, et al. (April 1998). "Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data". European Journal of Clinical Pharmacology. 54 (2): 177–83. doi: 10.1007/s002280050442 . PMID   9626925. S2CID   6508614.
  22. 1 2 "Zonegran 25, 50, 100 mg Hard Capsules". Electronic Medicines Compendium (eMC). Archived from the original on 14 February 2019. Retrieved 12 April 2017.
  23. ↑ Leppik IE (December 2004). "Zonisamide: chemistry, mechanism of action, and pharmacokinetics". Seizure. 13 (Suppl 1): S5–9, discussion S10. doi: 10.1016/j.seizure.2004.04.016 . PMID   15511691. S2CID   13458791.
  24. ↑ Mimaki T, Suzuki Y, Tagawa T, Karasawa T, Yabuuchi H (March 1990). "Interaction of zonisamide with benzodiazepine and GABA receptors in rat brain". Medical Journal of Osaka University. 39 (1–4): 13–7. PMID   1369646.
  25. ↑ Mimaki T, Suzuki Y, Tagawa T, Karasawa T, Yabuuchi H (March 1990). "[3H]zonisamide binding in rat brain". Medical Journal of Osaka University. 39 (1–4): 19–22. PMID   1369647.
  26. ↑ Ueda Y, Doi T, Tokumaru J, Willmore LJ (August 2003). "Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures". Brain Research. Molecular Brain Research. 116 (1–2): 1–6. doi:10.1016/S0169-328X(03)00183-9. PMID   12941455.
  27. ↑ "Zonisamide". www.drugbank.ca. Archived from the original on 2019-01-31. Retrieved 2019-01-31.
  28. ↑ Ohmori S, Nakasa H, Asanome K, Kurose Y, Ishii I, Hosokawa M, et al. (May 1998). "Differential catalytic properties in metabolism of endogenous and exogenous substrates among CYP3A enzymes expressed in COS-7 cells". Biochimica et Biophysica Acta (BBA) - General Subjects. 1380 (3): 297–304. doi:10.1016/s0304-4165(97)00156-6. PMID   9555064.
  29. ↑ Stiff DD, Robicheau JT, Zemaitis MA (January 1992). "Reductive metabolism of the anticonvulsant agent zonisamide, a 1,2-benzisoxazole derivative". Xenobiotica. 22 (1): 1–11. doi:10.3109/00498259209053097. PMID   1615700.
  30. ↑ Shah J, Kent S, Daniel MC (2002-06-15) [1972]. "Zonisamide". In René H, Levy RH, Brian SM, Perrucca E (eds.). Antiepileptic Drugs (Fifth ed.). Philadelphia: Lippincott Williams & Wilkins. p. 873. ISBN   0-7817-2321-3. Archived from the original on 2021-08-27. Retrieved 2007-11-07.
  31. ↑ Dainippon Sumitomo Pharma Co. Ltd. (2005). "Company History". Company Information. Dainippon Sumitomo Co., Ltd. Archived from the original on 13 February 2006. Retrieved 12 November 2005.
  32. ↑ Dainippon Pharmaceutical Co. Ltd. (2004). "Transfer of Rights Agreement for North America and Europe Reached on Zonegran". News Releases for Dainippon Pharmaceutical in 2004. Dainippon Sumitomo Pharma Co., Ltd. Archived from the original on 13 February 2006. Retrieved 12 November 2005.
  33. ↑ Dainippon Pharmaceutical Co. Ltd. (2005). "Dainippon Pharmaceutical and Eisai Conclude Agreement for the Development, Manufacture and Marketing of the Anti-Epileptic Agent Zonisamide in Asia". Dainippon Pharmaceutical News Releases for 2005. Dainippon Sumitomo Pharma Co., Ltd. Archived from the original on 22 February 2006. Retrieved 12 November 2005.
  34. ↑ Eisai Co. Ltd. (2005). "Eisai Announces Launch of Zonegran (zonisamide), Treatment For Epilepsy In the UK and Germany". Eisai 2005 News Releases. Eisai Co., Ltd. Archived from the original on 2005-10-28. Retrieved 12 November 2005.
  35. ↑ Iwata Y, Irie S, Uchida H, Suzuki T, Watanabe K, Iwashita S, et al. (April 2012). "Effects of zonisamide on tardive dyskinesia: a preliminary open-label trial". Journal of the Neurological Sciences. 315 (1–2): 137–40. doi:10.1016/j.jns.2011.12.010. PMID   22285275. S2CID   460261.
  36. ↑ Gadde KM, Franciscy DM, Wagner HR, Krishnan KR (April 2003). "Zonisamide for weight loss in obese adults: a randomized controlled trial". JAMA. 289 (14): 1820–5. doi:10.1001/jama.289.14.1820. PMID   12684361.
  37. ↑ University of Cincinnati (2005). "Zonegran in the Treatment of Binge Eating Disorder Associated With Obesity". ClinicalTrials.gov. Archived from the original on 2006-10-13. Retrieved 2006-05-04.
  38. ↑ Tuscaloosa Research, Education Advancement Corporation (2005). "Zonegran for the Treatment of Weight Gain Associated With Psychotropic Medication Use: A Placebo-Controlled Trial". ClinicalTrials.gov. Archived from the original on 2007-05-04. Retrieved 2006-05-04.
  39. ↑ National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2006). "Zonisamide for Weight Reduction in Obese Adults". ClinicalTrials.gov. Archived from the original on 2006-10-11. Retrieved 2006-05-04.
  40. ↑ "Bupropion/zonisamide". AdisInsight. Springer. 20 May 2017. Archived from the original on 19 August 2017. Retrieved 19 August 2017.
  41. ↑ Loftus BD (2004). "Zonegran". Archived from the original on 2008-10-23. Retrieved 2006-11-29.
  42. ↑ Hasegawa H (May 2004). "Utilization of zonisamide in patients with chronic pain or epilepsy refractory to other treatments: a retrospective, open label, uncontrolled study in a VA hospital". Current Medical Research and Opinion. 20 (5): 577–80. doi:10.1185/030079904125003313. PMID   15140322. S2CID   43580909.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.